This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.
HealthdirectFree Australian health advice you can count on. — Description, Dosage, Side Effects | PillsCard
Rx
HealthdirectFree Australian health advice you can count on.
150 mg, Proszek do sporządzania koncentratu do przygotowania roztworu do infuzji
INN: Trastuzumabum
Data updated: 2026-04-13
Available in:
🇨🇿🇩🇪🇬🇧🇯🇵🇵🇱🇸🇰
Form
Proszek do sporządzania koncentratu do przygotowania roztworu do infuzji
Dosage
150 mg
Route
dożylna
Storage
—
User Reviews
Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
About This Product
Manufacturer
Samsung Bioepis NL B.V. (Dania)
Composition
Trastuzumabum 150 mg
ATC Code
L01FD01
Source
URPL
(
ARTG
)
Ontruzant is indicated for the treatment of HER2-positive early breast cancer following surgery, and in association with chemotherapy and, if applicable, radiotherapy.
Ontruzant is indicated for the treatment of HER2-positive locally advanced breast cancer in combination with neoadjuvant chemotherapy followed by adjuvant Ontruzant.
Ontruzant is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress HER2:
a. as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease;
b. in combination with taxanes for the treatment of those patients who have not received chemotherapy for their metastatic disease; or
c. in combination with an aromatase inhibitor for the treatment of post-menopausal patients with hormone-receptor positive metastatic breast cancer.
Ontruzant is indicated in combination with cisplatin and either capecitabine or 5-FU for the treatment of patients with HER2-positive advanced adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.
PillsCard reference image